C

CSL

Develops and delivers biotherapies and vaccines

GLP Vendor Oversight and QA Lead

Full-TimeUpdated on 10/21/2026
No salary listed
Mid
Bachelor's
King of Prussia, PA, USA+5 moreMore locations: Maidenhead, UK | Melbourne VIC, Australia | Holly Springs, NC, USA | Broadmeadows, Australia | Parkville, Australia
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in a relevant scientific discipline is required.
  • At least 3 years of GxP quality experience with direct vendor/CRO oversight and/or auditing in GLP, GCP, or GMP is required; nonclinical/GLP experience is preferred.
  • Knowledge of OECD GLP, 21 CFR Part 58, Annex 11/Part 11, and data integrity (ALCOA+) is required.
  • Strong communication and negotiation skills are required.
  • Ability to work with limited supervision across multinational teams is required.
  • Strong analytical, problem-solving, influencing, and organisational skills are required.
  • Knowledge of QMS implementation, regulatory frameworks, and audit/inspection management is required.
Responsibilities
  • Own quality oversight of external partners supporting nonclinical and GLP activities, including CROs, laboratories, and test facilities.
  • Lead the vendor lifecycle, including due diligence, qualification, quality agreements, risk-based monitoring, issue management, and continuous improvement, ensuring adherence to GLP/GCP/GMP, data integrity, and applicable regulations.
  • Run risk-based qualification and requalification, draft and maintain Quality Agreements, and set vendor KPIs and governance forums, ensuring actions and CAPAs are closed.
  • Identify and prioritise vendors for audit on a risk basis; confirm vendor CAPAs are fit for purpose and run effectiveness checks. Coordinate inspection readiness and front- and back-room support.
  • Ensure vendor practices meet GLP/GCP/GMP, OECD GLP, 21 CFR Part 58, ICH, ISO, and data integrity (ALCOA+). Provide input on third-party deviations, change control, CAPA, and the QMS.
  • Lead vendor risk assessments, including risk registers and FMEA, to set oversight frequency, improve vendor performance, and present trends at management reviews.
  • Embed quality requirements in scopes of work and contracts, guide technology transfers and data flows, and train internal stakeholders.
  • Stay current with GLP and GxP regulations and translate changes into CSL requirements.
  • Partner with Nonclinical Development, Procurement, Legal, and IT.
Desired Qualifications
  • Nonclinical/GLP experience is preferred.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Oct 21st, 2026
CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO on $1.9M base salary

CSL Limited has appointed Deborah Waterhouse as chief executive officer and managing director, effective February 1, 2027. The board's decision followed a global search and was unanimous. Waterhouse has led ViiV Healthcare, an HIV specialist majority owned by GSK, since 2017. ViiV had sales of £7.7 billion in GSK's 2025 financial year. She also serves as president of GSK Global Health and previously ran GSK's US vaccines and primary care businesses. Her base salary will be £1,500,000 a year. She will stay based in the UK. Gordon Naylor will remain interim chief executive until then, before returning to the board as a non-executive director.

Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.